Dhanvantri Jeevan RekhaBOM:531043 -0.46%56 ROA % is 6.83% as of Mar. 2026, which is 277% above its 10-year median of 1.81. GuruFocus rates BOM:531043 with a GF Score™ of 56/100 and a GF Value™ of ₹24.92 (Fairly Valued). The stock has 3 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Dhanvantri Jeevan Rekha ranks better than 52.86% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Dhanvantri Jeevan Rekha's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹12.0 Mil.
Dhanvantri Jeevan Rekha's average Total Assets over the quarter that ended in Mar. 2026 was ₹175.7 Mil. Therefore, Dhanvantri Jeevan Rekha's annualized ROA % for the quarter that ended in Mar. 2026 was 6.83%.
The historical rank and industry rank for Dhanvantri Jeevan Rekha's ROA % or its related term are showing as below:
BOM:531043'
s ROA % Range Over the Past 10 Years
Min: -9.92 Med: 1.81 Max: 4.46
Current: 2.43
During the past 13 years, Dhanvantri Jeevan Rekha's highest ROA % was 4.46%. The lowest was -9.92%. And the median was 1.81%.
BOM:531043's ROA % is ranked better than 52.86% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 1.77
vs BOM:531043: 2.43
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Dhanvantri Jeevan Rekha's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dhanvantri Jeevan Rekha ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dhanvantri Jeevan Rekha's ROA % distribution charts can be found below:
* The bar in red indicates where Dhanvantri Jeevan Rekha's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Dhanvantri Jeevan Rekha (BOM:531043) has a ROA % of 6.83% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Dhanvantri Jeevan Rekha and its competitors. This is 277% above median its historical median of 1.81. According to the industry distribution chart, Dhanvantri Jeevan Rekha ranks #322 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 47.1%.
Is Dhanvantri Jeevan Rekha's ROA % too high?
Dhanvantri Jeevan Rekha's current ROA % of 6.83% is 277% above median its 10-year median of 1.81. The Healthcare Providers & Services industry median ROA % is 1.77. Dhanvantri Jeevan Rekha's value of 6.83% is 285.9% above this industry median. Based on the distribution chart, Dhanvantri Jeevan Rekha ranks #322 out of 683 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Dhanvantri Jeevan Rekha has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dhanvantri Jeevan Rekha's ROA % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dhanvantri Jeevan Rekha ranks #322 out of 683 companies for ROA %. This puts Dhanvantri Jeevan Rekha in the upper half of its industry. The industry median ROA % is 1.77. Dhanvantri Jeevan Rekha's value of 6.83% is 285.9% above this benchmark. While the company's 10-year median is 1.81 vs. the industry median of 1.77, Dhanvantri Jeevan Rekha has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.77, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dhanvantri Jeevan Rekha's current ROA % of 6.83% is 285.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Dhanvantri Jeevan Rekha and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dhanvantri Jeevan Rekha's current ROA % is 6.83%, which is 277% above median its own 10-year median of 1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dhanvantri Jeevan Rekha stock overvalued right now?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha (BOM:531043) is currently considered Fairly Valued. The stock's GF Value™ is ₹24.92, compared to a current price of ₹26.25 — trading 5.3% above its estimated fair value. The current ROA % is 6.83%, which is 277% above median its 10-year median of 1.81 and 285.9% above the Healthcare Providers & Services industry median of 1.77. Dhanvantri Jeevan Rekha's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Dhanvantri Jeevan Rekha (BOM:531043), the current ROA % is 6.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dhanvantri Jeevan Rekha (BOM:531043) Overvalued in 2026?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha stock appears to be overvalued.
The current stock price of ₹26.25 is trading 5.3% above its estimated GF Value™ of ₹24.92.
GuruFocus considers Dhanvantri Jeevan Rekha to be Fairly Valued.
Key valuation signals for BOM:531043:
ROA %: 6.83% (277% above median its 10-year median of 1.81)
GF Value™: ₹24.92 vs. price of ₹26.25 (5.3% above fair value)
Industry Position: 285.9% above the Healthcare Providers & Services median (#322 of 683)
No single metric tells the full story. See the BOM:531043 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dhanvantri Jeevan Rekha Ltd is engaged in providing diagnostic and therapeutic services and has extended its scope of diagnostic and hospital services by providing a fully operational Cath Lab, catering to higher end needs of the cardiac patients including Angiography, Angioplasty, Pacemaker Implantation, Valvuloplasty etc. The hospital has expanded its services to include a wide range of specialties such as Cardiology, Neurology, Orthopedics, Radiology, Gastroenterology, General Surgery, Urology, and General Medicine.
56GF Score
Get the complete analysis for BOM:531043
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531043 has been successfully added to your 
